Title |
Pediatric ulcerative colitis: current treatment approaches including role of infliximab
|
---|---|
Published in |
Biologics: Targets & Therapy, June 2012
|
DOI | 10.2147/btt.s31833 |
Pubmed ID | |
Authors |
Gia M Bradley, Maria Oliva-Hemker |
Abstract |
Ulcerative colitis is a chronic inflammatory bowel disease that can lead to derangements in the growth, nutritional status, and psychosocial development of affected children. There are several medical options for the induction and maintenance of disease remission, but the benefits of these medications need to be carefully weighed against the risks, especially in the pediatric population. As the etiology of the disease has become increasingly understood, newer therapeutic alternatives have arisen in the form of biologic therapies, which are monoclonal antibodies targeted to a specific protein or receptor. This review will discuss the classical treatments for children with ulcerative colitis, including 5-aminosalicylates, corticosteroids, thiopurine immunomodulators, and calcineurin inhibitors, with a particular focus on the newer class of anti-tumor necrosis factor-α agents. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 3 | 50% |
Saudi Arabia | 1 | 17% |
Unknown | 2 | 33% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 5 | 83% |
Practitioners (doctors, other healthcare professionals) | 1 | 17% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 2% |
Germany | 1 | 2% |
Qatar | 1 | 2% |
Unknown | 52 | 95% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Other | 5 | 9% |
Student > Ph. D. Student | 4 | 7% |
Researcher | 4 | 7% |
Student > Master | 3 | 5% |
Student > Postgraduate | 2 | 4% |
Other | 6 | 11% |
Unknown | 31 | 56% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 14 | 25% |
Nursing and Health Professions | 3 | 5% |
Agricultural and Biological Sciences | 3 | 5% |
Immunology and Microbiology | 1 | 2% |
Computer Science | 1 | 2% |
Other | 2 | 4% |
Unknown | 31 | 56% |